- The US FDA’s approval is based on four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002), which demonstrated efficacy, safety and tolerability of Ubrelvy (50, 100mg) for the acute treatment of migraine with/-out aura in adults
- The studies resulted in meeting its 1EPs i.e, elimination in migraine pain and the most bothersome symptom (nausea, hypersensitivity to light and sound), providing lasting relief up to 24 hrs.
- Ubrelvy is the first orally administered CGRP receptor antagonist (gepant), act without constricting blood vessels with no potential to cause addiction. The therapy is expected to be available in Q1’20
Click here to read full press release/ article | Ref: Allergan | Image: Nove.firenze